Our Work

Concentrating On The Cure

Who We Work With

Our Unique Approach

The Osteosarcoma Institute takes a differentiated approach. World renowned osteosarcoma experts came together in 2015 to establish OSI as a virtual institute to review the most breakthrough and promising ideas in osteosarcoma in a way that has never been done before. As a virtual institute, the Osteosarcoma Institute and our strategic board are not limited by geography, primary institutions, or traditional review methods. The Osteosarcoma Institute is free to set the agenda in osteosarcoma research and is limited only by the imaginations of the brightest minds in the field.

N

Remove Obstacles

Remove obstacles to identifying a cure by pre-funding pre-clinical studies and revolutionary fast readout trials of unexplored aspects of osteosarcoma

N

Fund Advancements

Fund clinical trials, translational grants, and osteosarcoma science to identify new treatment options for osteosarcoma patients for whom the first line of therapy has failed

N

Accelerate Progress

Work together with the research, pharma, and clinical communities, monitor and develop the scientific landscape around OS to identify opportunities and accelerate progress

N

Raise Awareness

Raise awareness and galvanize advocacy of osteosarcoma in communities across the United States

Lizzy, Age 9, OSI Patient Family Fund Honoree

OSI Funded Work

Preventing Metastases

Ryan D. Roberts, MD, PhD
Principal investigator for the Center for Childhood Cancer and Blood Diseases at The Research Institute at Nationwide Children’s Hospital

Commenced August 2020, this laboratory study works to identify the communication that must occur between osteosarcoma tumor cells and the normal lung to allow lung metastatic disease to occur. The hope is that understanding these communications could identify potential new drug targets to inhibit growth of lung metastases in osteosarcoma.

($500,000 – The Research Institute at Nationwide Children’s Hospital)  

Blocking Osteosarcoma

Study Conducted By Peter Scacheri, PhD
Member, GI Cancer Genetics Program, Case Comprehensive Cancer Center

Commenced February 2020, this laboratory study evaluates the potential role of new mechanisms to inhibit a gene required for cells to proliferate, called CDK4, to block the ability of osteosarcoma to metastasize.

($500,000 – Case Western Reserve University)

Developing New Drugs

Study Conducted By Katherine Janeway, MD
Director of Clinical Genomics and Senior Physician, Dana-Farber Cancer Institute

Commenced in January 2020, this study will evaluate the combination of two drugs that inhibit DNA repair pathways critical to the survival of osteosarcoma cells. This is the first study to test this combination in osteosarcoma patients.

($800,000 – Dana-Farber Cancer Institute)

Applying New Drug Concepts

Study Conducted By Richard Gorlick, MD
Division Head, Division of Pediatrics, The University of Texas MD Anderson Cancer Center

Commenced August 2020, this is a laboratory study to develop new drugs called antibody drug conjugates, or ADCs, combining a drug payload linked to a targeting antibody that will specifically deliver the anticancer drug to osteosarcoma cells. Antibody drug conjugates are a brand new, very promising technology. ADCs are a way to build drugs that has never been done before and have had amazing success in some cancers.

($500,000 – MD Anderson Cancer Center)

Novel Drug Combinations

Study Conducted By J. Andrew Livingston, MD, MS
Co-Director, Department of Adolescent and Young Adult Oncology, The University of Texas MD Anderson Cancer Center

Commenced December 2020, this study will evaluate the combination of two drugs with unique mechanisms of action in an attempt to harness the immune system to attack osteosarcoma tumors in patients. This is the first use of this combination of drugs in osteosarcoma patients.

($200,000 – MD Anderson Cancer Center)

Revolutionizing Patient Support

Commenced April 2019, this was the initial investment to begin offering support and guidance through the osteosarcoma Institute Hotline to patients, families, and physicians free of cost.

($128,000 – Honor Health Research Institute)

Unlocking Immunotherapy for Osteosarcoma

 

Study conducted by Elias Sayour, MD, PhD, Assistant Professor in the UF departments of Neurosurgery and Pediatrics at the University of Florida

ToDetails to be announced Soon commence in 2021, this study has developed a novel RNA-nanoparticle (RNA-NP) vaccine that simultaneously penetrates/reprograms the tumor microenvironment while inducing an OS specific T cell response. This vaccine utilizes a novel engineering design that layers tumor derived mRNA into a lipid-nanoparticle (NP) “onion-like” package. These NPs enable maximal isolated and stable packaging of mRNA into a fixed volume for easy distribution, cell- penetration, uncoating, and quickly boosts innate/adaptive immune responses against a personalized tumor mRNA cohort.

($400,000 – University of Florida)

Testing Liquid Biopsy in OS

In this study, we will take advantage of two early-phase clinical trials in osteosarcoma in which serial blood samples will be collected for liquid biopsy studies. In this work, we plan to study circulating tumor cells collected prior to thDetails to be Announced Soonerapy and during therapy to measure relevant proteomic changes in the patient’s cancer cells in response to targeted therapy. These studies will validate the methodologies for identifying and profiling CTCs in patients with osteosarcoma and also demonstrate the feasibility of profiling protein expression levels in single CTCs in longitudinal samples.

(Dana-Farber Cancer Institute)

Harnessing Natural Killer Cells

Study Conducted by Daniel A. Vallera, PhD, Professor of Therapeutic Radiology-Radiation Oncology, Department of Radiation Oncology, University of Minnesota

Details to be Announced SoonThis study provides an innovative approach to enhance the immune response to better target osteosarcoma through targeting B7-H3, a member of the B7-family of checkpoint ligands with B7-H1 (PD-L1), which attenuates immune anticancer responses by inhibiting T cell activation, proliferation and cytokine production.

(University of Minnesota)

Patient Stories

Before You Go

Sign-up for our newsletter and stay up-to-date about our fight against Osteosarcoma!

Translate »